|
1
|
World Health Organization, . International
Agency for Research on Cancer. Press Release No. 224. Lyon/London:
3–February. 2014
|
|
2
|
Minna JD and Schiller JH: Lung Cancer:
Harrison's Principles of Internal Medicine (17th edition). 551–562.
2008.
|
|
3
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L; and
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions, : The
IASLC lung cancer staging project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirata Y, Moore GW, Bertagna C and Orth
DN: Plasma concentrations of immunoreactive human epidermal growth
factor (urogastrone) in man. J Clin Endocrinol Metab. 50:440–444.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xiqing Li, Zunlan Zhao, Mingyue Liu, et
al: Epidermal growth factor affects the growth and proliferation of
non-small cell lung cancer A549 and H23 cells. Chinese Journal of
applied diagnosis and treatment. 29:562–564. 2015.(In Chinese).
|
|
7
|
Bethune G, Bethune D, Ridgway N and Xu Z:
Epidermal growth factor receptor (EGFR) in lung cancer: An overview
and update. J Thorac Dis. 2:48–51. 2010.PubMed/NCBI
|
|
8
|
Lee HJ, Xu X, Choe G, Chung DH, Seo JW,
Lee JH, Lee CT, Jheon S, Sung SW and Chung JH: Protein
overexpression and gene amplification of epidermal growth factor
receptor in nonsmall cell lung carcinomas: Comparison of four
commercially available antibodies by immunohistochemistry and
fluorescence in situ hybridization study. Lung Cancer. 68:375–382.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsu CP, Lee LW, Tang SC, Hsin IL, Lin YW
and Ko JL: Epidermal growth factor activates telomerase activity by
direct binding of Ets-2 to hTERT promoter in lung cancer cells.
Tumour Biol. 36:5389–5398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen W, Lu J, Qin Y, Wang J, Tian Y, Shi
D, Wang S, Xiao Y, Dai M, Liu L, et al: Ret finger protein-like 3
promotes tumor cell growth by activating telomerase reverse
transcriptase expression in human lung cancer cells. Oncotarget.
5:11909–11923. 2014.PubMed/NCBI
|
|
11
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Murray SA, Yang S, Demicco E, Ying H,
Sherr DH, Hafer LJ, Rogers AE, Sonenshein GE and Xiao ZX: Increased
expression of MDM2, cyclin D1, and p27Kip1 in
carcinogen-induced rat mammary tumors. J Cell Biochem. 95:875–884.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anderson D, Koch CA, Grey L, Ellis C,
Moran MF and Pawson T: Binding of SH2 domains of phospholipase C
gamma 1, GAP, and Src to activated growth factor receptors.
Science. 250:979–982. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuqin Hao and Huixia Zheng: The mechanism
research of MAPK/ERK signaling pathways in cancer treatment. China
J Leprosy and Skin Diseases. 7:490–493. 2012.(In Chinese).
|
|
16
|
Roberts PJ and Stinchcombe TE: KRAS
mutation: Should we test for it, and does it matter? J Clin Oncol.
31:1112–1121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Loboda A, Nebozhyn M, Klinghoffer R,
Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M,
Haines B, et al: A gene expression signature of RAS pathway
dependence predicts response to PI3K and RAS pathway inhibitors and
expands the population of RAS pathway activated tumors. BMC Med
Genomics. 3:262010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matallanas D and Crespo P: New druggable
targets in the Ras pathway? Curr Opin Mol Ther. 12:674–683.
2010.PubMed/NCBI
|
|
19
|
Bonnefont J, Nikolaev SI, Perrier AL, Guo
S, Cartier L, Sorce S, Laforge T, Aubry L, Khaitovich P, Peschanski
M, et al: Evolutionary forces shape the human RFPL1,2,3
genes toward a role in neocortex development. Am J Hum Genet.
83:208–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan BH and Suzuki Y, Takahashi H, Ying PH,
Takahashi C, Han Q, Chin WX, Chao SH, Sawasaki T, Yamamoto N and
Suzuki Y: Identification of RFPL3 protein as a novel E3 ubiquitin
ligase modulating the integration activity of human
immunodeficiency virus, type 1 preintegration complex using a
microtiter plate-based assay. J Biol Chem. 289:26368–26382. 2014.
View Article : Google Scholar : PubMed/NCBI
|
